Abstract
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease of children and adolescents with primary joints involvement and various manifestations. Uveitis is of extra-articular signs characterized by eye inflammation. Standard antirheumatic drugs in combination with local therapy are effective in 60%. When these drugs are ineffective, genetically engineered drugs are used in JIA with rheumatoid uveitis.
Highlights
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease of children and adolescents with primary joints involvement and various manifestations
Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
Standard antirheumatic drugs in combination with local therapy are effective in 60%. When these drugs are ineffective, genetically engineered drugs are used in JIA with rheumatoid uveitis. This prospective observation was aimed to assessing effectiveness and safety of adalimumab(ADA) in the treatment of juvenile idiopathic arthritis associated with uveitis in patients with severe JIA, prolonged disease and resistance to standard antirheumatic therapy
Summary
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease of children and adolescents with primary joints involvement and various manifestations. Uveitis is of extra-articular signs characterized by eye inflammation. Standard antirheumatic drugs in combination with local therapy are effective in 60%. When these drugs are ineffective, genetically engineered drugs are used in JIA with rheumatoid uveitis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
